Norbert Klause

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

Dagmar Kubitza, Michael Becka, Wolfgang Mueck et al. · British Journal of Clinical Pharmacology · 2010 · 431 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +16

Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic–uraemic syndrome: an analysis of the German STEC-HUS registry

Jan T. Kielstein, Gernot Beutel, Susanne Fleig et al. · Nephrology Dialysis Transplantation · 2012 · 236 citations · Full text

Medicine, Infectious Diseases, Internal Medicine +14

Pharmacokinetics of Teneligliptin in Subjects With Renal Impairment

Atef Halabi, Haidar Maatouk, Karl Ernst Siegler et al. · Clinical Pharmacology in Drug Development · 2013 · 39 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Hypoxic Renal Tissue Damage by Endothelin-Mediated Arterial Vasoconstriction during Radioangiography in Man

Norbert Klause, Thomas Arendt, Markus Lins et al. · Advances in experimental medicine and biology · 1998 · 26 citations

Medicine, Nephrology, Radiology +13

Effects of Renal Impairment on the Pharmacology of Rivaroxaban (BAY 59-7939) - An Oral, Direct, Factor Xa Inhibitor.

Atef Halabi, Haidar Maatouk, Norbert Klause et al. · Blood · 2006 · 23 citations

Pharmacy, Pharmacokinetics, Pharmacology +16